Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.65 |
| ▸ | AR | P10275 | 14/20 | 0.57 |
| ▸ | TNKS | O95271 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31496045 | 0.87 | AR (0.54) | PGRARACACBEPHX2 | |
| SCHEMBL31496041 | 0.86 | PGR (0.48) | PGRARACACBEPHX2 | |
| SCHEMBL31496048 | 0.85 | PGR (0.47) | PGRARACACB | |
| SCHEMBL29547208 | 0.83 | AR (0.67) | PGRARTNKSPARP1PARP2 | |
| SCHEMBL24267313 | 0.82 | PGR (0.72) | PGRARTNKSPARP1PARP2 | |
| SCHEMBL26802464 | 0.81 | PGR (0.61) | PGRARTNKSPARP1PARP2 | |
| SCHEMBL24267600 | 0.81 | PGR (0.64) | PGRARTNKSPARP1PARP2 | |
| SCHEMBL31496042 | 0.81 | PGR (0.43) | PGRARACACBEPHX2 | |
| SCHEMBL26802462 | 0.81 | PGR (0.61) | PGRARTNKSPARP1PARP2 | |
| SCHEMBL20046695 | 0.79 | PGR (0.62) | PGRARTNKSPARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-05-01 | — | — | US | claimed |
| WO-2025081092-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | claimed |
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025081092-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136578-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | AR, SHBG, FSHR | PGR 73/4885AR 1/4885TNKS 2294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.